Vertex receives a positive PBAC recommendation for reimbursement of ORKAMBI®
Vertex announces it has received the PBAC recommendation for ORKAMBI® (lumacaftor/ivacaftor) to be listed on the Pharmaceutical Benefits Scheme in Australia for people ages six and over with cystic fibrosis who have two copies of the F508del mutation. August 20, 2018